Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5985
    +0.0009 (+0.16%)
     
  • NZD/EUR

    0.5538
    +0.0005 (+0.10%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • NZD/JPY

    90.4380
    +0.0450 (+0.05%)
     

Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

Will Demand for Rapid COVID-19 Tests Help Abbott Laboratories Beat the Market in 2022?

In particular, Abbott Laboratories (NYSE: ABT) makes BinaxNOW kits, which are the most popular rapid coronavirus antigen diagnostic test in the U.S. Are things different this time as a result of the omicron variant wave, or is Abbott on track to disappoint? Coronavirus rapid testing revenue has been all over the place, appearing to ebb and flow based on the public's perceptions about where the pandemic is headed.